COMP <GO>
IMVT vs CRSP // ALTMAN Z-SCORE & DEBT/EQUITY
Immunovant Inc. (NASDAQ) VS. CRISPR Therapeutics AG (NASDAQ) • 15-METRIC TALLY: IMVT 6
— CRSP 5
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: IMVT
LAST: $29.64 (+0.75%) • MKT CAP: $6.12B
balance-sheet
26.00
LAST: $54.26 (+0.28%) • MKT CAP: $5.25B
balance-sheet
7.97
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMVT VS. CRSP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMVT | CRSP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -30.60% | -4.40 | CRSP | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.65% | -6.59% | -0.06 | CRSP | /fcf-yield <GO> |
| Operating Margin | -36.00% | -60.00% | +24.00 | IMVT | /operating-margins <GO> |
| Net Profit Margin | -29.50% | -60.00% | +30.50 | IMVT | /net-margins <GO> |
| Revenue Growth (YoY) | 9.90% | -65.00% | +74.90 | IMVT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 7.97 | +18.03 | IMVT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | IMVT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.1 | 54.9 | -11.80 | CRSP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.12 | -0.14 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 28.0x | +8.00 | CRSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.12B | $5.25B | $875.7M | IMVT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMVT REV | CRSP REV | IMVT GROSS % | CRSP GROSS % | IMVT FCF | CRSP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $3.5M | — | — | -$407.3M | -$345.9M |
| FY 2024 | $0 | $37.3M | — | — | -$376.6M | -$144.7M |
| FY 2023 | $0 | $371.2M | — | — | -$214.2M | -$277.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMVT // BETA 0.98
CRSP // BETA 1.12